Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Targeting the transcription factor receptor LXR to treat clear cell renal cell carcinoma: agonist or inverse agonist?

Wu G, Wang Q, Xu Y, Li J, Zhang H, Qi G, Xia Q.

Cell Death Dis. 2019 May 28;10(6):416. doi: 10.1038/s41419-019-1654-6.

2.

Long non-coding RNA HOTTIP promotes renal cell carcinoma progression through the regulation of the miR-615/IGF-2 pathway.

Wang Q, Wu G, Zhang Z, Tang Q, Zheng W, Chen X, Chen F, Li Q, Che X.

Int J Oncol. 2018 Nov;53(5):2278-2288. doi: 10.3892/ijo.2018.4539. Epub 2018 Aug 23.

PMID:
30226576
3.

Sorafenib induces renal cell carcinoma apoptosis via upregulating activating transcription factor 4.

Wang Q, Wu G, Che X, Li Q, Zhang Z, Tang Q.

Pharmazie. 2018 Mar 5;73(3):156-160. doi: 10.1691/ph.2018.7855.

PMID:
29544563
4.

In vitro anticancer activities of osthole against renal cell carcinoma cells.

Liu L, Mao J, Wang Q, Zhang Z, Wu G, Tang Q, Zhao B, Li L, Li Q.

Biomed Pharmacother. 2017 Oct;94:1020-1027. doi: 10.1016/j.biopha.2017.07.155. Epub 2017 Aug 12.

PMID:
28810525

Supplemental Content

Loading ...
Support Center